Not recruiting

Study on the Safety and Effectiveness of Durvalumab, Paclitaxel, and Drug Combinations for Patients with Metastatic Triple Negative Breast Cancer

Verified siteRegistered drugNo placebo

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying treatments for metastatic triple-negative breast cancer (TNBC), a type of breast cancer that does not have the usual hormone receptors or the HER2 protein. The study involves several medications, including Durvalumab (also known as MEDI4736), Paclitaxel, Datopotamab deruxtecan, Oleclumab (MEDI9447), Capivasertib, and DS-8201a (Trastuzumab deruxtecan). These treatments are being tested to see how safe and effective they are when used alone or in combination.

The purpose of the study is to evaluate the safety and effectiveness of these treatments for patients with TNBC. The study is divided into two parts. In the first part, the focus is on understanding the safety and how well patients tolerate the combination of Durvalumab with other new cancer treatments, with or without Paclitaxel. The second part aims to assess how effective these combinations are in treating the cancer. Participants will receive the treatments through intravenous infusions or oral tablets, depending on the specific medication being tested.

Throughout the study, participants will be monitored for any side effects and changes in their health. The study will also track how the cancer responds to the treatments, looking for signs of improvement or progression. This research aims to find better treatment options for those with metastatic triple-negative breast cancer, offering hope for improved outcomes in the future.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Enrollment
Upon joining the study, eligibility is confirmed based on specific criteria such as age, gender, and medical condition.
The condition being studied is Stage IV Triple Negative Breast Cancer, a type of breast cancer lacking certain receptors.
Step 2
Initial assessment
An initial assessment is conducted to establish baseline health status. This includes physical examinations and laboratory tests.
Step 3
Treatment phase 1
The first part of the treatment involves receiving durvalumab and possibly other therapies such as paclitaxel.
Durvalumab is administered as a solution for infusion, meaning it is given through a vein.
Step 4
Treatment phase 2
In the second phase, the focus is on assessing the effectiveness of the treatment combinations.
The treatment may include additional novel oncology therapies, which are new cancer treatments being tested.
Step 5
Monitoring and follow-up
Throughout the trial, regular monitoring is conducted to track health status and any side effects.
This includes checking vital signs, conducting laboratory tests, and performing physical examinations.
Step 6
Completion and evaluation
At the end of the trial, a final evaluation is performed to assess the overall response to the treatment.
The main outcomes measured include the objective response rate, which is the percentage of patients with a significant reduction in cancer size.

Who can join the trial?

8 criteria

Must be female.
Must be at least 18 years old at the time of screening.
Must have a diagnosis of advanced or metastatic Triple Negative Breast Cancer (TNBC), which means the cancer has spread and cannot be removed by surgery.
Must not have received any prior treatment for Stage IV TNBC, which is the most advanced stage of breast cancer.
Must have at least one measurable lesion, which is an area of cancer that can be accurately measured and has not been treated with radiation.
Must have a WHO/ECOG status of 0 or 1 at enrollment, which indicates the level of daily activity and ability to care for oneself. A status of 0 means fully active, and 1 means restricted in physically strenuous activity but able to carry out light work.
For patients in Arm 6 (durvalumab and DS-8201a): Must provide documentation showing advanced or metastatic TNBC with HER2 low tumor expression. This means the cancer cells have low levels of a protein called HER2.
For patients in Arm 8 (durvalumab + Dato-DXd): Must have a PD-L1 positive tumor, which means the tumor has a protein that may help the cancer hide from the immune system.

Who cannot join the trial?

3 criteria

Patients who have a different type of breast cancer that is not Triple Negative Breast Cancer (TNBC). TNBC is a type of breast cancer that does not have certain proteins like estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2.
Patients who are male, as the study is only for female participants.
Patients who are considered part of a vulnerable population, which means they might need special protection or care.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Centrum Onkologii Ziemi Lubelskiej Im. Sw. Jana Z Dukli
Verified
Lublin, Poland
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy
Verified
Cracow, Poland
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki W Krakowie
Verified
Cracow, Poland

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Durvalumab
is a medication used in this trial to help the immune system detect and fight cancer cells. It is a type of immunotherapy that targets a specific protein on the surface of cancer cells, helping the body's immune system to attack and destroy them.
Paclitaxel
is a chemotherapy drug used in this trial to stop the growth of cancer cells. It works by interfering with the normal function of microtubules during cell division, which prevents cancer cells from multiplying and spreading.
Novel Oncology Therapies
are new treatments being tested in this trial alongside durvalumab and paclitaxel. These therapies are designed to target specific pathways or mechanisms in cancer cells, potentially improving the effectiveness of treatment and offering new options for patients with metastatic triple-negative breast cancer.

What is already known about the treatment

Durvalumab
This medication is administered intravenously and is currently being studied in clinical trials for its effectiveness in treating metastatic triple-negative breast cancer. It is an immunotherapy drug that works by blocking a protein called PD-L1, which helps cancer cells evade the immune system. By inhibiting this protein, durvalumab enhances the body's immune response against cancer cells. It is classified as a monoclonal antibody and is being evaluated for its safety and efficacy in combination with other oncology therapies.
Paclitaxel
This medication is also administered intravenously and is widely used in the treatment of various cancers, including breast cancer. It works by inhibiting cell division, which prevents cancer cells from growing and spreading. Paclitaxel is classified as a chemotherapy drug, specifically a taxane, and is often used in combination with other treatments to enhance its effectiveness. In the context of the clinical trial, it is being combined with durvalumab to assess its potential benefits in treating metastatic triple-negative breast cancer.

Investigated diseases

Triple Negative Breast Cancer – This is a subtype of breast cancer that does not express the estrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2. It is known for its aggressive nature and rapid growth. Unlike other breast cancer types, it does not respond to hormonal therapy or therapies that target HER2 receptors. The disease often presents at a higher stage and can spread more quickly to other parts of the body. It is more common in younger women and those with a BRCA1 gene mutation. The progression of this cancer can vary, but it typically requires a combination of treatments to manage.